Alden Alberto Moccia

Divisione di oncologia medica Istituto oncologico della Svizzera Italiana (IOSI) Locarno – Bellinzona - Mendrisio Bellinzona, CH Divisione di oncologia medica Istituto oncologico della Svizzera Italiana (IOSI) Locarno – Bellinzona - Mendrisio Bellinzona, CH Specialist in Medical Oncology and Internal Medicine HIGHLIGHTS He studied medicine in Lausanne (Switzerland) where he graduated in 2000. He trained in medical oncology and internal medicine at the Oncology Institute of Southern Switzerland (IOSI), the University Hospital of Lausanne and the British Columbia Cancer Agency, in Vancouver, Canada. He is author and co-author of several publications in peer-reviewed journals, site principal investigator for several clinical trials and the Swiss Coordinating Investigator for SAKK of the HD21 phase III trial. CLINICAL ACTIVITY He is a senior physician in the Lymphoma Unit of the Oncology Institute of Southern Switzerland (IOSI). Clinical activity in the field of medical oncology, with a specific focus on diagnosis and treatment of hematological malignancies, in particular, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. RESEARCH ACTIVITY He is an active member of the International Extranodal Study Group (IELSG), of the Lymphoma Project Group of the Swiss Group of Clinical Cancer Research (SAKK) and of the local organizing committee of the International Conference on Malignant Lymphoma (ICML). His research activity has been devoted to Hodgkin lymphoma and non-Hodgkin lymphoma with well-established previous experience in the development and completion of retrospective surveys. In 2012, he published with the Vancouver group in the Journal of Clinical Oncology a validation of the International Prognostic Project Score (IPS) in 740 patients with HL treated with ABVD. Since 2015, he is the representative of the Swiss Group of Clinical Cancer Research (SAKK) within the German Hodgkin Lymphoma Study Group (GHSG) and he is the Swiss Coordinating Investigator for SAKK of the HD21 trial. He has been an abstract reviewer for the ICML and for the European Hematology Association (EHA) annual meeting.